Matinas BioPharma Holdings (MTNB) Receivables - Net (2018 - 2021)
Matinas BioPharma Holdings (MTNB) posted quarterly Receivables - Net of $980000.0 for Q3 2021, up 991.16% quarter-over-quarter from $89813.0 in Q2 2018.
Matinas BioPharma Holdings (MTNB) Receivables - Net (2018 - 2021) Analysis & Trends
Matinas BioPharma Holdings (MTNB) has reported Receivables - Net for 2 consecutive years, with $980000.0 the latest figure, recorded in Q3 2021.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.88 Bn | 132.03 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 86.62 Bn | 78.62 Bn | 3.93 Bn |
| 3 | Argenx Se | 65.28 Bn | 60.10 Bn | 1.37 Bn |
| 4 | Moderna | 61.39 Bn | 56.25 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 42.11 Bn | 37.01 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.37 Bn | 28.06 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.76 Bn | 10.37 Bn | 668.28 Mn |
| 8 | Insmed | 27.46 Bn | 26.30 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.24 Bn | 26.41 Bn | - |
| 10 | Matinas BioPharma Holdings | 1.20 Mn | 385,035.87 | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2021 | 980,000.00 |
| Sep 30, 2021 | 980,000.00 |
| Jun 30, 2018 | 89,813.00 |
| Jun 30, 2018 | 89,813.00 |